Skip to main content
SpringerLink
Log in

Pharmacokinetic and Pharmacoimmunodynamic Interactions Between Prednisolone and Sirolimus in Rabbits

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To assess pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone (Pred, 1 mg/kg) and sirolimus (Sir, 0.25 mg/kg) in rabbits.

Methods. After intravenous administration, plasma concentrations of Pred and corticosterone, and Sir blood concentrations were followed for 24 hours along with blood granulocyte and T-helper cell counts. Ex vivo and in vitro whole blood lymphocyte proliferation marked lymphocyte reactivity.

Results. Pred terminal half-life and clearance were 1.1 hr and 0.72 l/ hr/kg with no difference after Sir. Sir values were 13 hr and 0.16 1/hr/ kg and Pred produced no changes. Corticosterone production (0−12hr) was suppressed by 55% after Pred alone or combined, while Sir did not cause adrenal suppression. Blood T-helper cells and granulocytes displayed circadian rhythms after placebo. Over 12 hr, T-helper cell counts were decreased by Pred (40%) and Sir (19%) while granulocyte numbers increased by 56% and 23%. After coadministration, cell numbers were similar to Pred alone. Pred and Sir decreased lymphocyte reactivity by 41% and 56% over 24 hr and their combination reached 85% inhibition with additive interaction. In vitro studies showed antagonistic or synergistic interactions depending on drug concentration ratios.

Conclusions. At therapeutic concentrations, Sir and Pred do not significantly interact pharmacokinetically and have additive pharmacoimmunodynamics. Thus, the therapeutic application of this combination is promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. R. E. Morris. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant. Rev. 6:39–87 (1992).

    Google Scholar 

  2. S. M. Metclafe and F. M. Richards. Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 49:798–803 (1990).

    PubMed  Google Scholar 

  3. D. T. Boumpas, F. Paliogianni, E. D. Anastassiou, and J. E. Balow. Glucocorticoid action on the immune system: molecular and cellular aspects. Clin. Exp. Rheumatol. 9:413–423 (1991).

    PubMed  Google Scholar 

  4. G. M. Ferron and W. J. Jusko. Species and gender-related differences in cyclosporine/prednisolone/sirolimus interaction in whole blood lymphocyte proliferation assays. J. Pharmacol. Exp. Ther. 286:191–200 (1998).

    PubMed  Google Scholar 

  5. K. H. Lew, E. A. Ludwig, M. A. Milad, K. Donovan, E. Middleton, J. J. Ferry, and W. J. Jusko. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 54:402–414 (1993).

    PubMed  Google Scholar 

  6. W. J. Jusko, G. M. Ferron, S. M. Mis, B. D. Kahan, and J. J. Zimmerman. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J. Clin. Pharmacol. 36:1100–1106 (1996).

    PubMed  Google Scholar 

  7. M. Sattler, P. Guengerich, C.-H. Yun, U. Christians, and K.-F. Sewing. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20:753–761 (1992).

    PubMed  Google Scholar 

  8. F. J. Frey and B. M. Frey. Urinary 6β-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J. Lab. Clin. Med. 101:593–604 (1983).

    PubMed  Google Scholar 

  9. I. A. Shah, P. H. Whiting, G. Omar, A. W. Thomson, and M. D. Burke. Effects of FK506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant. Proc. 23:2783–2785 (1991).

    PubMed  Google Scholar 

  10. M. L. Rocci, N. F. Johnson, and W. J. Jusko. Serum protein binding of prednisolone in four species. J. Pharm. Sci. 69:977–978 (1980).

    PubMed  Google Scholar 

  11. W. Piekoszewski, F. S. Chow, and W. J. Jusko. Disposition of tacrolimus (FK506) in rabbits: role of red blood cell binding in hepatic clearance. Drug Metabl. Dispos. 21:690–698 (1993).

    Google Scholar 

  12. G. M. Ferron and W. J. Jusko. Species differences in sirolimus stability in humans, rabbits and rats. Drug Metab. Dispos. 26:83–84 (1998).

    PubMed  Google Scholar 

  13. J. A. Wald and W. J. Jusko. Prednisolone pharmacodynamics: leukocyte trafficking in the rat. Life Sci. 55:371–378 (1994).

    Google Scholar 

  14. W. Piekoszewski, F. S. Chow, and W. J. Jusko. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. J. Pharmacol. Exp. Ther. 269:103–109 (1994).

    PubMed  Google Scholar 

  15. W. J. Jusko, N. A. Pyszczynski, M. S. Bushway, R. D'Ambrosio, and S. M. Mis. Fifteen years of operation of high-performance liquid chromatograpic assay for prednisolone, cortisol and prednisone in plasma. J. Chromatogr. B. 658:47–54 (1994).

    Google Scholar 

  16. G. M. Ferron, W. D. Conway, and W. J. Jusko. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (rapamycin) determination. J. Chromatogr. B. 703:243–251 (1997).

    Google Scholar 

  17. B. Drewinko, T. L. Loo, B. Brown, J. A. Gottlieb, and E. J. Freireich. Combination chemotherapy in vitro with adriamycin. Observation of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Can. Biochem. Biophys. 1:187–195 (1976).

    Google Scholar 

  18. W. R. Greco, H. S. Park, and Y. M. Rustum. Application of a new approach for the quantitation of drug synergism to the combination of cisdiamminedichloroplatinium and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 50:5318–5327 (1990).

    PubMed  Google Scholar 

  19. L. E. Gerlowski and R. K. Jain. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72:1103–1127 (1983).

    PubMed  Google Scholar 

  20. B. C. Frey, W. F. J. Frey, and A. L. de Weck. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. J. Immunol. 133:2479–2487 (1984).

    PubMed  Google Scholar 

  21. R. Yatscoff, D. LeGatt, R. Keenan, and P. Chackowsky. Blood distribution of rapamycin. Transplanatation 56:1202–1206 (1993).

    Google Scholar 

  22. J. E. Kay, E. Sampore-Kwaters, F. Geraghty, and G. Y. Morgan. Uptake of FK506 by lymphocytes and erythrocytes. Transplant. Proc. 23:2760 (1991).

    PubMed  Google Scholar 

  23. F. S. Chow, W. Piekoszewski, and W. J. Jusko. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Drug Metab. Dispos. 25:610–616 (1997).

    PubMed  Google Scholar 

  24. R. W. Yatscoff, P. Wang, K. Chan, D. Hicks, and J. Zimmerman. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations. Ther. Drug Monit. 17:666–671 (1995).

    PubMed  Google Scholar 

  25. M. A. Milad, E. A. Ludwig, S. Anne, E. Middleton, and W. J. Jusko. Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte traficking. J. Pharmacokinet. Biopharm. 22:469–480 (1994).

    PubMed  Google Scholar 

  26. Y. M. Ning and E. R. Sanchez. Immunophilins, heat shock proteins, and glucocorticoid receptor actions in vivo. Methods 9:188–200 (1996).

    PubMed  Google Scholar 

  27. A. S. Shoker. Immunopharmacologic therapy in renal transplantation. Pharmacotherapy 16:562–575 (1996).

    PubMed  Google Scholar 

  28. D. E. Hricik, W. Y. Almawi, and T. B. Strom. Trends in the use of glucocorticoids in renal transplantation. Transplantation 57:979–989 (1994).

    PubMed  Google Scholar 

  29. M. G. Murgia, S. Jordan, and B. D. Kahan. The side effect profile of sirolimus: a phase I study in quiescent cyclosporin-prednisone treated renal transplant patients. Kidney Int. 49:209–216 (1996).

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Geraldine M. Ferron

    Present address: Clinical Pharmacokinetic Department, Wyeth-Ayerst Research, King of Prussia Road, Radnor, Pennsylvania

Authors and Affiliations

  1. Department of Pharmaceutics, State University of New York at Buffalo, Buffalo, New York

    Geraldine M. Ferron & William J. Jusko

Authors
  1. Geraldine M. Ferron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Jusko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferron, G.M., Jusko, W.J. Pharmacokinetic and Pharmacoimmunodynamic Interactions Between Prednisolone and Sirolimus in Rabbits. Pharm Res 15, 1888–1894 (1998). https://doi.org/10.1023/A:1011966308791

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011966308791

Search

Navigation